Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Core Insights - The collaboration between EVA Pharma and Eli Lilly aims to provide affordable insulin to one million people with diabetes in low- to middle-income countries by 2030 [1][5] - The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking the first regulatory approval for EVA Pharma's insulin products [2][3] - Lilly has supplied active pharmaceutical ingredients at reduced prices and provided technology transfer to enable local manufacturing of insulin [2][3] Company Developments - EVA Pharma has established a new biologics manufacturing facility and completed insulin formulations and stability testing [3] - The company is also seeking WHO pre-qualification for its human insulin injection to ensure high-quality standards [4] - Lilly and EVA Pharma have expanded their collaboration to include the manufacturing of treatments for immunological diseases across 56 countries [6] Strategic Goals - The collaboration is part of Lilly's 30x30 initiative, which aims to improve healthcare access for 30 million people in resource-limited settings by 2030 [5] - EVA Pharma's CEO emphasized the importance of localizing essential medicines to drive equitable healthcare access [5] - The partnership is expected to impact over a million lives annually across 56 countries, demonstrating the potential of collaborative efforts in healthcare [5]